Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
PLoS One ; 10(5): e0126648, 2015.
Article in English | MEDLINE | ID: mdl-25955177

ABSTRACT

LHX4 is a LIM homeodomain transcription factor involved in the early steps of pituitary ontogenesis. To date, 8 heterozygous LHX4 mutations have been reported as responsible of combined pituitary hormone deficiency (CPHD) in Humans. We identified 4 new LHX4 heterozygous allelic variants in patients with congenital hypopituitarism: W204X, delK242, N271S and Q346R. Our objective was to determine the role of LHX4 variants in patients' phenotypes. Heterologous HEK293T cells were transfected with plasmids encoding for wild-type or mutant LHX4. Protein expression was analysed by Western Blot, and DNA binding by electro-mobility shift assay experiments. Target promoters of LHX4 were cotransfected with wild type or mutant LHX4 to test the transactivating abilities of each variant. Our results show that the W204X mutation was associated with early GH and TSH deficiencies and later onset ACTH deficiency. It led to a truncated protein unable to bind to alpha-Gsu promoter binding consensus sequence. W204X was not able to activate target promoters in vitro. Cotransfection experiments did not favour a dominant negative effect. In contrast, all other mutants were able to bind the promoters and led to an activation similar as that observed with wild type LHX4, suggesting that they were likely polymorphisms. To conclude, our study underlines the need for functional in vitro studies to ascertain the role of rare allelic variants of LHX4 in disease phenotypes. It supports the causative role of the W204X mutation in CPHD and adds up childhood onset ACTH deficiency to the clinical spectrum of the various phenotypes related to LHX4 mutations.


Subject(s)
Hypopituitarism/genetics , LIM-Homeodomain Proteins/genetics , Mutation , Transcription Factors/genetics , Adrenocorticotropic Hormone/deficiency , Alleles , Child , Child, Preschool , Female , Growth Hormone/deficiency , HEK293 Cells , Heterozygote , Humans , Hypopituitarism/complications , Infant , Male , Thyrotropin/deficiency
2.
PLoS One ; 10(3): e0120010, 2015.
Article in English | MEDLINE | ID: mdl-25822178

ABSTRACT

To test the role of wtPIT-1 (PITWT) or PIT-1 (R271W) (PIT271) in somatolactotroph cells, we established, using inducible lentiviral vectors, sublines of GH4C1 somatotroph cells that allow the blockade of the expression of endogenous PIT-1 and/or the expression of PITWT or PIT271, a dominant negative mutant of PIT-1 responsible for Combined Pituitary Hormone Deficiency in patients. Blocking expression of endogenous PIT-1 induced a marked decrease of cell proliferation. Overexpressing PITWT twofold led also to a dose-dependent decrease of cell proliferation that was accompanied by cell death. Expression of PIT271 induced a strong dose-dependent decrease of cell proliferation accompanied by a very pronounced cell death. These actions of PIT271 are independent of its interaction/competition with endogenous PIT-1, as they were unchanged when expression of endogenous PIT-1 was blocked. All these actions are specific for somatolactotroph cells, and could not be observed in heterologous cells. Cell death induced by PITWT or by PIT271 was accompanied by DNA fragmentation, but was not inhibited by inhibitors of caspases, autophagy or necrosis, suggesting that this cell death is a caspase-independent apoptosis. Altogether, our results indicate that under normal conditions PIT-1 is important for the maintenance of cell proliferation, while when expressed at supra-normal levels it induces cell death. Through this dual action, PIT-1 may play a role in the expansion/regression cycles of pituitary lactotroph population during and after lactation. Our results also demonstrate that the so-called "dominant-negative" action of PIT271 is independent of its competition with PIT-1 or a blockade of the actions of the latter, and are actions specific to this mutant variant of PIT-1.


Subject(s)
Somatotrophs/physiology , Transcription Factor Pit-1/physiology , Adenoma/genetics , Adenoma/pathology , Adenoma/physiopathology , Amino Acid Sequence , Amino Acid Substitution , Animals , Apoptosis/physiology , Base Sequence , Cell Line , Cell Proliferation/physiology , Cell Survival/genetics , Cell Survival/physiology , Chlorocebus aethiops , Humans , Lactotrophs/cytology , Lactotrophs/physiology , Molecular Sequence Data , Mutant Proteins/genetics , Mutant Proteins/physiology , Pituitary Neoplasms/genetics , Pituitary Neoplasms/pathology , Pituitary Neoplasms/physiopathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , Rats , Somatotrophs/cytology , Transcription Factor Pit-1/antagonists & inhibitors , Transcription Factor Pit-1/genetics , Tumor Cells, Cultured
3.
Mol Biochem Parasitol ; 198(2): 71-4, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25619800

ABSTRACT

The scarcity of molecular tools for genetic manipulation is a critical obstacle for functional genomics studies on Trypanosoma cruzi. The current study adapted an inducible site-specific recombination system based on Dimerizable CRE recombinase (DiCRE). Two vectors for stable transfection were created, a first one to express inactive portions of DiCRE recombinase, and a second plasmid containing the loxP sites to test DiCRE activity. After integrating both constructs into the T. cruzi genome, it was shown that DiCRE recombinase can be efficiently used to manipulate its genome by allowing the removal of selectable markers thus generating homogeneous populations. The DiCRE recombinase success allows conditional knockout and the removal of selectable markers without prior parasite modification, which also facilitate the transferring of DiCRE recombinase to different T. cruzi strains.


Subject(s)
Genetics, Microbial/methods , Molecular Biology/methods , Recombination, Genetic , Trypanosoma cruzi/genetics , Genetic Markers , Selection, Genetic , Transfection
4.
Mol Microbiol ; 88(4): 687-701, 2013 May.
Article in English | MEDLINE | ID: mdl-23489321

ABSTRACT

Asexual blood stages of the malaria parasite, which cause all the pathology associated with malaria, can readily be genetically modified by homologous recombination, enabling the functional study of parasite genes that are not essential in this part of the life cycle. However, no widely applicable method for conditional mutagenesis of essential asexual blood-stage malarial genes is available, hindering their functional analysis. We report the application of the DiCre conditional recombinase system to Plasmodium falciparum, the causative agent of the most dangerous form of malaria. We show that DiCre can be used to obtain rapid, highly regulated site-specific recombination in P. falciparum, capable of excising loxP-flanked sequences from a genomic locus with close to 100% efficiency within the time-span of a single erythrocytic growth cycle. DiCre-mediated deletion of the SERA5 3' UTR failed to reduce expression of the gene due to the existence of alternative cryptic polyadenylation sites within the modified locus. However, we successfully used the system to recycle the most widely used drug resistance marker for P. falciparum, human dihydrofolate reductase, in the process producing constitutively DiCre-expressing P. falciparum clones that have broad utility for the functional analysis of essential asexual blood-stage parasite genes.


Subject(s)
Gene Deletion , Genetics, Microbial/methods , Integrases/metabolism , Molecular Biology/methods , Parasitology/methods , Plasmodium falciparum/genetics , Gene Expression , Genes, Protozoan , Integrases/genetics , Plasmodium falciparum/growth & development , Recombination, Genetic
5.
Nat Methods ; 10(2): 125-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23263690

ABSTRACT

We established a conditional site-specific recombination system based on dimerizable Cre recombinase-mediated recombination in the apicomplexan parasite Toxoplasma gondii. Using a new single-vector strategy that allows ligand-dependent, efficient removal of a gene of interest, we generated three knockouts of apicomplexan genes considered essential for host-cell invasion. Our findings uncovered the existence of an alternative invasion pathway in apicomplexan parasites.


Subject(s)
Genome, Protozoan , Toxoplasma/genetics , Gene Knockout Techniques/methods , Host-Parasite Interactions/genetics , Integrases
6.
EMBO Rep ; 14(2): 113-4, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23258260
7.
Mol Endocrinol ; 26(8): 1455-63, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22638072

ABSTRACT

The pituitary transcription factor POU1F1 is required for the differentiation of lactotrope, thyrotrope, and somatotrope cells. Its expression is maintained in the adult and is crucial for the expression of prolactin, GH, and TSHß-subunit. Different studies indicated that POU1F1 could also have other functions in these cells. The identification of new targets of this factor could be useful to obtain a better understanding of these functions. To address this question we combined data obtained from expression microarrays and from chromatin immunoprecipitation (ChIP)-chips. Gene expression microarray assays were used to detect genes that have their expression modified in somatolactotrope GH4C1 cells by the expression of a dominant-negative form of POU1F1, POU1F1(R271W), and led to the identification of 1346 such genes. ChIP-chip experiments were performed from mouse pituitaries and identified 1671 POU1F1-binding sites in gene-promoter regions. Intersecting the gene expression and the ChIP-chip data yielded 121 potential new direct targets. The initial set of 1346 genes identified using the microarrays, as well as the 121 potential new direct targets, were analyzed with DAVID bioinformatics resource for gene ontology term enrichment and cluster. This analysis revealed enrichment in different terms related to protein synthesis and transport, to apoptosis, and to cell division. The present study represents an integrative genome-wide approach to identify new target genes of POU1F1 and downstream networks controlled by this factor.


Subject(s)
Transcription Factor Pit-1/metabolism , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Amino Acid Substitution , Animals , Chromatin Immunoprecipitation , Cyclic AMP Response Element Modulator/genetics , Cyclic AMP Response Element Modulator/metabolism , Female , Gene Expression Regulation , Gene Regulatory Networks , Genes, Dominant , Genome, Human , HEK293 Cells , HeLa Cells , Humans , LIM Domain Proteins/genetics , LIM Domain Proteins/metabolism , Mice , Mice, Inbred C57BL , Oligonucleotide Array Sequence Analysis , Pregnancy , Promoter Regions, Genetic , Protein Binding , Transcription Factor Pit-1/genetics , Transcription, Genetic , Transcriptome
8.
Biotechniques ; 51(4): 267-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21988693

ABSTRACT

We developed a new approach to prepare DNA probes for electrophoretic mobility gel shift assays that presents a number of advantages compared with the classical approach. The method relies on two complementary oligonucleotides containing the desired transcription factor binding sequence, one of them being extended at its 3' end with a universal tail that complements a third, short oligonucleotide labeled with a fluorophore or any other label. The use of this third "universal" oligonucleotide allows labeling many different probes with minimal time, effort and cost. We show that probes prepared this way are as effective and reliable as probes prepared by conventional methods. We refer to this short oligonucleotide as LUEGO for labeled universal electrophoretic gel shift oligonucleotide.


Subject(s)
Electrophoretic Mobility Shift Assay/methods , Oligonucleotide Probes/genetics , Oligonucleotides/genetics , Protein Binding/genetics , Base Sequence , Binding Sites , DNA/metabolism , DNA Probes/genetics , Fluorescent Dyes/chemistry , Molecular Sequence Data , Oligonucleotides/metabolism , Sensitivity and Specificity
9.
J Mol Endocrinol ; 46(1): 9-19, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20978111

ABSTRACT

The bicoid-like transcription factor PITX2 has been previously described to interact with the pituitary-specific POU homeodomain factor POU1F1 (human ortholog of PIT-1) to achieve cell-specific expression of prolactin (PRL) and GH in pituitary somatolactotroph cells. In this work, we have investigated the functional properties of three PITX2 mutants reported in Axenfeld-Rieger syndrome patients relative to the regulation of these genes, using reporter genes under the control of human PRL (hPRL), hGH, or POU1F1 promoters transfected in nonpituitary and pituitary cell lines. Among the three mutations studied, Y167X and E101X introduce a premature stop codon, and F104L leads to an amino acid substitution. While PITX2(E101X) is not expressed in the cells following transfection, and PITX2(F104L) is functionally inactive, the PITX2(Y167X) mutant keeps its DNA-binding capacity and displays a markedly enhanced activation of the hPRL and POU1F1 promoters, but not of the hGH promoter. Y167X is the first mutation of PITX2 described to result in a differential effect on the activation of its different physiological targets, hPRL and POU1F1 on one hand and hGH on the other hand. The differential effect of the Y167X mutation might be linked to an interaction of PITX2 with different transcription factors or cofactors when bound to the hPRL and POU1F1 or the hGH promoters. These results might form the basis for the identification of the PITX2 protein complex necessary for the differential GH or PRL expression.


Subject(s)
Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Human Growth Hormone/genetics , Prolactin/genetics , Promoter Regions, Genetic , Transcription Factor Pit-1/genetics , Transcription Factors/genetics , Transcription Factors/metabolism , Animals , Anterior Eye Segment/abnormalities , Blotting, Western , Cell Line , Electrophoretic Mobility Shift Assay , Eye Abnormalities/genetics , Eye Diseases, Hereditary , Human Growth Hormone/metabolism , Humans , Mutation , Pituitary Gland/metabolism , Prolactin/metabolism , Transcription Factor Pit-1/metabolism , Transcriptional Activation , Homeobox Protein PITX2
10.
Genesis ; 46(4): 193-9, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18395834

ABSTRACT

We examined the use of ERT2-iCre-ERT2 (Cre2ERT2), a tamoxifen-regulated form of Cre that has been described to have a background activity lower than that of other tamoxifen-regulated Cre constructs, for establishing performant conditional deleter mouse lines. Cre2ERT2 was inserted by homologous recombination into the Rosa26 locus. These mice were mated with R26R Cre-reporter mice. No recombination could be observed in the progenies in the absence of tamoxifen treatment. Tamoxifen treatment at E13-14 led to a high level, albeit variable, recombination in most of the tissues examined: liver, heart, kidney, brain, lung etc. Treatment of adult animals also induced recombination in these tissues, although at a lower level. Northern blot and qPCR studies suggested that these differences are not linked to significant variations of the level of expression of Cre2ERT2. Thus, Cre2ERT2 appears to be a good alternative to existing modulatable Cre systems, displaying a lack of background activity and a high-level inducibility in vivo.


Subject(s)
Gene Transfer Techniques , Integrases/genetics , Animals , Cells, Cultured , Female , Humans , Mice , Mice, Inbred C57BL , Mice, Transgenic , Proteins/genetics , RNA, Untranslated , Recombination, Genetic/genetics
11.
PLoS One ; 2(12): e1355, 2007 Dec 26.
Article in English | MEDLINE | ID: mdl-18159238

ABSTRACT

Cre recombinase is extensively used to engineer the genome of experimental animals. However, its usefulness is still limited by the lack of an efficient temporal control over its activity. We have recently developed a conceptually new approach to regulate Cre recombinase, that we have called Dimerizable Cre or DiCre. It is based on splitting Cre into two inactive moieties and fusing them to FKBP12 (FK506-binding protein) and FRB (binding domain of the FKBP12-rapamycin associated protein), respectively. These latter can be efficiently hetero-dimerized by rapamycin, leading to the reinstatement of Cre activity. We have been able to show, using in vitro approaches, that this ligand-induced dimerization is an efficient way to regulate Cre activity, and presents a low background activity together with a high efficiency of recombination following dimerization. To test the in vivo performance of this system, we have, in the present work, knocked-in DiCre into the Rosa26 locus of mice. To evaluate the performance of the DiCre system, mice have been mated with indicator mice (Z/EG or R26R) and Cre-induced recombination was examined following activation of DiCre by rapamycin during embryonic development or after birth of progenies. No recombination could be observed in the absence of treatment of the animals, indicating a lack of background activity of DiCre in the absence of rapamycin. Postnatal rapamycin treatment (one to five daily injection, 10 mg/kg i.p) induced recombination in a number of different tissues of progenies such as liver, heart, kidney, muscle, etc. On the other hand, recombination was at a very low level following in utero treatment of DiCrexR26R mice. In conclusion, DiCre has indeed the potentiality to be used to establish conditional Cre-deleter mice. An added advantage of this system is that, contrary to other modulatable Cre systems, it offers the possibility of obtaining regulated recombination in a combinatorial manner, i.e. induce recombination at any desired time-point specifically in cells characterized by the simultaneous expression of two different promoters.


Subject(s)
Integrases/genetics , Animals , Base Sequence , Cells, Cultured , DNA Probes , Dimerization , Embryonic Development , Enzyme Activation , Integrases/chemistry , Integrases/metabolism , Mice , Sirolimus/pharmacology , Tacrolimus Binding Protein 1A/metabolism
12.
Nucleic Acids Res ; 31(21): e131, 2003 Nov 01.
Article in English | MEDLINE | ID: mdl-14576331

ABSTRACT

Cre recombinase is extensively used to engineer the genome of experimental animals. However, its usefulness is still limited by the lack of an efficient temporal control over its activity. To overcome this, we have developed DiCre, a regulatable fragment complementation system for Cre. The enzyme was split into two moieties that were fused to FKBP12 (FK506-binding protein) and FRB (binding domain of the FKBP12-rapamycin-associated protein), respectively. These can be efficiently heterodimerized by rapamycin. Several variants, based on splitting Cre at different sites and using different linker peptides, were tested in an indicator cell line. The fusion proteins, taken separately, had no recombinase activity. Stable transformants, co-expressing complementing fragments based on splitting Cre between Asn59 and Asn60, displayed low background activity affecting 0.05-0.4% of the cells. Rapamycin induced a rapid recombination, reaching 100% by 48-72 h, with an EC50 of 0.02 nM. Thus, ligand-induced dimerization can efficiently regulate Cre, and should be useful to achieve a tight temporal control of its activity, such as in the case of the creation of conditional knock-out animals.


Subject(s)
Integrases/chemistry , Integrases/metabolism , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Viral Proteins/chemistry , Viral Proteins/metabolism , Amino Acid Sequence , Animals , Cell Line , Dimerization , Gene Expression Regulation, Enzymologic/drug effects , Genetic Complementation Test , Integrases/genetics , Ligands , Models, Molecular , Peptide Fragments/genetics , Protein Structure, Quaternary/drug effects , Rats , Sequence Deletion/genetics , Sirolimus/pharmacology , Transfection , Viral Proteins/genetics
13.
Exp Neurol ; 175(1): 49-60, 2002 May.
Article in English | MEDLINE | ID: mdl-12009759

ABSTRACT

To prepare immortalized adrenal chromaffin cells for eventual clinical use, the immortalizing oncogene must be removed. We have utilized a Cre-mediated excision of a loxP-flanked Tag sequence to test whether immortalized chromaffin cells could be disimmortalized by this method. Cultures of embryonic rat adrenal cells were immortalized with the tsA-TN retroviral vector encoding the loxP-flanked temperature-sensitive allele of SV40 large T antigen (tsA-TN) and a positive/negative neo/HSV-TK sequence for selection with either G418 or gancyclovir, respectively. These cells were then infected with the 1710-CrePR1 bicistronic retroviral vector coding for a form of Cre modulatable by the synthetic steroid RU486. These immortalized loxTsTag/CrePR1/RAD cells expressed immunoreactivities (ir) for all the catecholamine enzymes: tyrosine hydroxylase (TH), dopamine beta-hydroxylase (DbetaH), and phenylethanolamine-N-methyltransferase (PNMT). After initial incubation at 37 degrees C with RU486 for 3 days, followed by the addition of gancyclovir for 7 days, Tag-ir was not detectable in most of the surviving chromaffin cells, compared to 100% expression in immortalized loxTsTag/CreR1/RAD cells not treated with RU486 and gancyclovir. The expression of TH, DbetaH, and PNMT was increased after disimmortalization and the ability of disimmortalized cells to synthesize norepinephrine was also significantly increased compared to immortalized cells. When both types of chromaffin cells were transplanted in a model of neuropathic pain and partial nerve injury, both cell grafts were equally able to reverse the behavioral hypersensitivity induced by the injury. The use of Cre/lox site-directed disimmortalization of chromaffin cells that are able to deliver neuroactive molecules offers a novel approach to cell therapy.


Subject(s)
Chromaffin Cells/transplantation , Integrases , Mutagenesis, Site-Directed , Pain Management , Recombination, Genetic , Sciatic Neuropathy/therapy , Viral Proteins , Animals , Antigens, Viral, Tumor/genetics , Cell Count , Cells, Cultured , Chromaffin Cells/cytology , Chromaffin Cells/drug effects , Disease Models, Animal , Dopamine beta-Hydroxylase/biosynthesis , Gene Expression/drug effects , Genetic Vectors/pharmacology , Hyperalgesia/etiology , Hyperalgesia/therapy , Integrases/genetics , Mifepristone/pharmacology , Norepinephrine/biosynthesis , Oncogenes/drug effects , Oncogenes/genetics , Pain/etiology , Phenylethanolamine N-Methyltransferase/biosynthesis , Rats , Rats, Inbred WF , Rats, Sprague-Dawley , Recombination, Genetic/drug effects , Sciatic Neuropathy/complications , Sciatic Neuropathy/physiopathology , Temperature , Thymidine Kinase/genetics , Transfection , Treatment Outcome , Tyrosine 3-Monooxygenase/biosynthesis , Viral Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...